Page 1

Xencor Reports Second Quarter 2021 Financial Results August 4 , 2021 -- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA , Calif .-- ( BUSINESS WIRE ) -- Aug . 4 , 2021-- Xencor , Inc. ( NASDAQ : XNCR ) , a clinical - stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases , today reported financial results for the second quarter ended June 30 , 2021 and provided a review of recent business and portfolio highlights . " Xencor is applying its leading protein engineering tools and XmAb technology to overcome historical challenges in creating therapeutic molecules from bispecific antibodies or cytokines . For our most advanced clinical programs , we recently initiated a Phase 2 clinical study for XmAb717 , our PD - 1 × CTLA - 4 bispecific antibody , in metastatic prostate cancer , and we plan to initiate a Phase 2 study of plamotamab in lymphoma . Our cytokine portfolio is rapidly advancing with XmAb306 , our long - acting IL - 15 for oncology , and XmAb564 , our IL - 2 for autoimmune disease , both of which are in Phase 1 studies , " said Bassil Dahiyat , Ph.D. , president and chief executive officer at Xencor . " We are also at the forefront of efforts to engage CD28 to selectively activate T cells , and we plan to initiate clinical studies in 2022 for XmAb808 , our B7 - H3 x CD28 bispecific antibody , as well as our third clinical cytokine program , an IL - 12 - Fc candidate . " " Additionally , Vir Biotechnology and GSK's sotrovimab was recently authorized for the treatment of mild - to - moderate COVID - 19 , becoming the third antibody incorporating XmAb technology to be made commercially available for patients . The licensing of our XmAb technologies expands their application to areas of medicine outside our internal focus and provides us with important sources of non - dilutive capital , which we use to advance and expand our broad internal portfolio of novel bispecific antibodies and cytokine drug candidates . " Recent Portfolio Highlights and Upcoming Data Presentations • XmAb717 ( PD - 1 x CTLA - 4 ) : A Phase 2 study was initiated for patients with metastatic castration - resistant prostate cancer . The study is evaluating XmAb717 as a monotherapy or in combination with other agents , depending on the tumor's molecular subtype . Later this year , the Company anticipates initiating new studies of XmAb717 in additional tumor types and plans to announce additional data from the Phase 1 expansion cohorts for prostate cancer and renal cell carcinoma , as well as a cohort with multiple tumor types . • Plamotamab ( CD20 x CD3 ) : The Company plans to initiate a clinical study to investigate the chemotherapy - free triple combination of plamotamab , tafasitamab and lenalidomide in patients with relapsed or refractory diffuse large B cell lymphoma , an aggressive form of non - Hodgkin lymphoma , in late 2021 or early 2022. Plamotamab , which redirects T cells to tumors , and tafasitamab , a CD19 - directed antibody , combine distinct immune pathways to generate a powerful anti - tumor effect and is a differentiated approach to treating patients with lymphomas . The Company plans to announce data from the ongoing Phase 1 study later this year . • Tidutamab ( SSTR2 x CD3 ) : A Phase 2 study was initiated for patients with Merkel cell carcinoma and small cell lung cancer , which are SSTR2 - expressing tumor types known to be responsive to immunotherapy and are cancers with high unmet medical need . Later this year , the Company plans to announce updated data from the Phase 1 expansion cohort in patients with neuroendocrine tumor patients , including longer clinical follow - up and updated biomarker data . • XmAb564 ( regulatory T cell selective IL - 2 - Fc ) : XmAb564 is a potency - reduced IL - 2 cytokine engineered to selectively activate regulatory T cells for the treatment of autoimmune disease and is fused to an XmAb Fc domain for extended half - life . A Phase 1 single - ascending dose clinical trial was started in May to evaluate the safety , pharmacokinetics and biomarkers activity of a subcutaneous dose in healthy volunteers . • XmAb819 ( ENPP3 x CD3 ) : XmAb819 is engineered with reduced - potency CD3 binding as well as a multivalent 2 + 1 bispecific antibody format to enable greater tumor selectivity . XmAb819 is in development for patients with renal cell carcinoma , and the Company plans to submit an investigational new drug ( IND ) application in 2021 and initiate a Phase 1 study in early 2022 .